{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Secondary+Acute+Myeloid+Leukemia",
    "query": {
      "condition": "Refractory Secondary Acute Myeloid Leukemia"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 348,
    "total_pages": 35,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Secondary+Acute+Myeloid+Leukemia&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-10T18:32:46.916Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00104923",
      "title": "Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Myeloproliferative Disorders",
        "Leukemia",
        "Lymphoma",
        "Multiple Myeloma and Plasma Cell Neoplasm"
      ],
      "interventions": [
        {
          "name": "fenretinide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "California Cancer Consortium",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 29,
      "start_date": "2005-02",
      "completion_date": "2017-04",
      "has_results": false,
      "last_update_posted_date": "2017-07-19",
      "last_synced_at": "2026-06-10T18:32:46.916Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Bethesda, Maryland • Houston, Texas + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Lubbock",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00104923"
    },
    {
      "nct_id": "NCT00424242",
      "title": "Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors",
        "Chronic Myeloproliferative Disorders",
        "Leukemia",
        "Lymphoma",
        "Lymphoproliferative Disorder",
        "Metastatic Cancer",
        "Multiple Myeloma and Plasma Cell Neoplasm",
        "Myelodysplastic Syndromes",
        "Precancerous Condition",
        "Secondary Myelofibrosis",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 15,
      "start_date": "2007-01",
      "completion_date": "2011-09",
      "has_results": false,
      "last_update_posted_date": "2021-09-08",
      "last_synced_at": "2026-06-10T18:32:46.916Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00424242"
    },
    {
      "nct_id": "NCT00084695",
      "title": "Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Childhood Langerhans Cell Histiocytosis",
        "Fanconi Anemia",
        "Leukemia",
        "Lymphoma",
        "Myelodysplastic Syndromes",
        "Neuroblastoma",
        "Sarcoma",
        "Unspecified Childhood Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "anti-thymocyte globulin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "busulfan",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "fludarabine phosphate",
          "type": "DRUG"
        },
        {
          "name": "melphalan",
          "type": "DRUG"
        },
        {
          "name": "methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Milton S. Hershey Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 25,
      "start_date": "2003-09",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2014-01-10",
      "last_synced_at": "2026-06-10T18:32:46.916Z",
      "location_count": 1,
      "location_summary": "Hershey, Pennsylvania",
      "locations": [
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00084695"
    },
    {
      "nct_id": "NCT01118013",
      "title": "Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia",
        "Lymphoma",
        "Lymphoproliferative Disorder",
        "Multiple Myeloma and Plasma Cell Neoplasm",
        "Myelodysplastic Syndromes",
        "Myelodysplastic/Myeloproliferative Neoplasms"
      ],
      "interventions": [
        {
          "name": "anti-thymocyte globulin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "donor lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "therapeutic allogeneic lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "busulfan",
          "type": "DRUG"
        },
        {
          "name": "fludarabine phosphate",
          "type": "DRUG"
        },
        {
          "name": "methotrexate",
          "type": "DRUG"
        },
        {
          "name": "mycophenolate mofetil",
          "type": "DRUG"
        },
        {
          "name": "tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "reduced-intensity transplant conditioning procedure",
          "type": "OTHER"
        },
        {
          "name": "allogeneic hematopoietic stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Alliance for Clinical Trials in Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "69 Years",
        "sex": "ALL",
        "summary": "Up to 69 Years"
      },
      "enrollment_count": 6,
      "start_date": "2010-12",
      "completion_date": "2013-08",
      "has_results": true,
      "last_update_posted_date": "2017-03-24",
      "last_synced_at": "2026-06-10T18:32:46.916Z",
      "location_count": 10,
      "location_summary": "Lewes, Delaware • Newark, Delaware • Orlando, Florida + 7 more",
      "locations": [
        {
          "city": "Lewes",
          "state": "Delaware"
        },
        {
          "city": "Newark",
          "state": "Delaware"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Elkton MD",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01118013"
    },
    {
      "nct_id": "NCT03009240",
      "title": "Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Recurrent Acute Myeloid Leukemia",
        "Refractory Acute Myeloid Leukemia",
        "Secondary Acute Myeloid Leukemia",
        "Therapy-Related Acute Myeloid Leukemia",
        "Untreated Adult Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Decitabine",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pevonedistat",
          "type": "DRUG"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2017-08-21",
      "completion_date": "2026-03-19",
      "has_results": false,
      "last_update_posted_date": "2026-04-22",
      "last_synced_at": "2026-06-10T18:32:46.916Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03009240"
    },
    {
      "nct_id": "NCT00079404",
      "title": "17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Undifferentiated Leukemia",
        "Recurrent Childhood Acute Lymphoblastic Leukemia",
        "Recurrent Childhood Acute Myeloid Leukemia",
        "Secondary Acute Myeloid Leukemia",
        "Unspecified Childhood Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "tanespimycin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "1 Year to 21 Years"
      },
      "enrollment_count": 36,
      "start_date": "2004-03",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-06-05",
      "last_synced_at": "2026-06-10T18:32:46.916Z",
      "location_count": 1,
      "location_summary": "Arcadia, California",
      "locations": [
        {
          "city": "Arcadia",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00079404"
    },
    {
      "nct_id": "NCT00949052",
      "title": "Genetic Susceptibility and Risk of Second Cancers in Patients Who Have Undergone Stem Cell Transplant for Cancer",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "DNA analysis",
          "type": "GENETIC"
        },
        {
          "name": "polymorphism analysis",
          "type": "GENETIC"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "medical chart review",
          "type": "OTHER"
        },
        {
          "name": "questionnaire administration",
          "type": "OTHER"
        },
        {
          "name": "assessment of therapy complications",
          "type": "PROCEDURE"
        },
        {
          "name": "evaluation of cancer risk factors",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Vanderbilt-Ingram Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 1000,
      "start_date": "2009-01",
      "completion_date": "2018-02",
      "has_results": false,
      "last_update_posted_date": "2018-08-16",
      "last_synced_at": "2026-06-10T18:32:46.916Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00949052"
    },
    {
      "nct_id": "NCT02115295",
      "title": "Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Biphenotypic Leukemia",
        "Acute Myeloid Leukemia",
        "Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
        "Blasts 10 Percent or More of Bone Marrow Nucleated Cells",
        "Blasts 10 Percent or More of Peripheral Blood White Cells",
        "de Novo Myelodysplastic Syndrome",
        "Myelodysplastic Syndrome",
        "Previously Treated Myelodysplastic Syndrome",
        "Recurrent Acute Myeloid Leukemia",
        "Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
        "Refractory Acute Myeloid Leukemia",
        "Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
        "Secondary Acute Myeloid Leukemia",
        "Untreated Adult Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Cladribine",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Gilteritinib",
          "type": "DRUG"
        },
        {
          "name": "Idarubicin",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Midostaurin",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 508,
      "start_date": "2014-05-19",
      "completion_date": "2030-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-20",
      "last_synced_at": "2026-06-10T18:32:46.916Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02115295"
    },
    {
      "nct_id": "NCT02727803",
      "title": "Personalized NK Cell Therapy in CBT",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
        "Acute Biphenotypic Leukemia",
        "Acute Lymphoblastic Leukemia",
        "Acute Lymphoblastic Leukemia in Remission",
        "Acute Myeloid Leukemia With Myelodysplasia-Related Changes",
        "Acute Myeloid Leukemia With Variant MLL Translocations",
        "B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1",
        "Chemotherapy-Related Leukemia",
        "Chronic Myelomonocytic Leukemia",
        "Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
        "High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements",
        "ISS Stage II Plasma Cell Myeloma",
        "ISS Stage III Plasma Cell Myeloma",
        "Myelodysplastic Syndrome",
        "Myelodysplastic Syndrome With Excess Blasts",
        "Myelodysplastic Syndrome With Gene Mutation",
        "Myelodysplastic/Myeloproliferative Neoplasm",
        "Previously Treated Myelodysplastic Syndrome",
        "Recurrent Acute Myeloid Leukemia",
        "Recurrent Adult Acute Myeloid Leukemia",
        "Recurrent Hodgkin Lymphoma",
        "Recurrent Non-Hodgkin Lymphoma",
        "Refractory Acute Lymphoblastic Leukemia",
        "Refractory Adult Acute Lymphoblastic Leukemia",
        "Secondary Acute Myeloid Leukemia",
        "Therapy-Related Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Allogeneic Natural Killer Cell Line NK-92",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Anti-Thymocyte Globulin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Clofarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine Phosphate",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Total-Body Irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Umbilical Cord Blood Transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER",
        "RADIATION",
        "PROCEDURE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "15 Years to 80 Years"
      },
      "enrollment_count": 100,
      "start_date": "2016-05-19",
      "completion_date": "2027-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-06-10T18:32:46.916Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02727803"
    },
    {
      "nct_id": "NCT00095797",
      "title": "XK469R in Treating Patients With Refractory Hematologic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adult Acute Basophilic Leukemia",
        "Adult Acute Eosinophilic Leukemia",
        "Adult Acute Megakaryoblastic Leukemia (M7)",
        "Adult Acute Minimally Differentiated Myeloid Leukemia (M0)",
        "Adult Acute Monoblastic Leukemia (M5a)",
        "Adult Acute Monocytic Leukemia (M5b)",
        "Adult Acute Myeloblastic Leukemia With Maturation (M2)",
        "Adult Acute Myeloblastic Leukemia Without Maturation (M1)",
        "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities",
        "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)",
        "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)",
        "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)",
        "Adult Acute Myelomonocytic Leukemia (M4)",
        "Adult Erythroleukemia (M6a)",
        "Adult Pure Erythroid Leukemia (M6b)",
        "Blastic Phase Chronic Myelogenous Leukemia",
        "Chronic Myelomonocytic Leukemia",
        "de Novo Myelodysplastic Syndromes",
        "Previously Treated Myelodysplastic Syndromes",
        "Recurrent Adult Acute Lymphoblastic Leukemia",
        "Recurrent Adult Acute Myeloid Leukemia",
        "Refractory Anemia With Excess Blasts",
        "Refractory Anemia With Excess Blasts in Transformation",
        "Refractory Chronic Lymphocytic Leukemia",
        "Relapsing Chronic Myelogenous Leukemia",
        "Secondary Myelodysplastic Syndromes",
        "Stage III Chronic Lymphocytic Leukemia",
        "Stage IV Chronic Lymphocytic Leukemia",
        "Untreated Adult Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "R(+)XK469",
          "type": "DRUG"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2004-10",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-02-08",
      "last_synced_at": "2026-06-10T18:32:46.916Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00095797"
    }
  ]
}